Skip to main content
IXICO PLC logo

IXICO PLC — Investor Relations & Filings

Ticker · IXI ISIN · GB00BFXR4C20 LEI · 2138005M1F59O6HWSA97 IL Professional, scientific and technical activities
Open in API
Filings indexed 354 across all filing types
Latest filing 2018-09-21 AGM Information
Country GB United Kingdom
Listing IL IXI

About IXICO PLC

https://www.ixico.com/

IXICO PLC is a clinical research and data analytics company specializing in neuroscience. It provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for neurological disorders. The company utilizes its proprietary, AI-driven technology platform to manage and analyze complex imaging and digital health data. This platform deploys disease-specific algorithms to generate reliable clinical data and precision insights, aiming to accelerate research and development decision-making, de-risk clinical studies, and support the advancement of new therapies for conditions such as Alzheimer's and Huntington's disease.

Recent filings

Filing Released Lang Actions
Result of General Meeting - Amended
AGM Information Classification · 1% confidence The document is an amendment to a previous announcement titled 'Results of General Meeting' (RNS No 5577B). It confirms that the Resolutions regarding the 'Capital Reorganisation' were duly passed at the General Meeting. It also details the expected admission of 'New Ordinary Shares' to trading and the resulting total number of voting rights. The core subject is the outcome of a shareholder vote following a General Meeting, which directly relates to the voting results of a general meeting. This aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions capital changes (CAP), the primary purpose of this specific filing is to report the outcome of the vote that approved those changes.
2018-09-21 English
Result of General Meeting
AGM Information Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing information via 'RNS, the news service of the London Stock Exchange'. The content announces the 'Result of General Meeting' where resolutions were passed, specifically concerning a 'Capital Reorganisation' and the subsequent admission of 'New Ordinary Shares' to trading. This announcement details the outcome of a shareholder vote and subsequent capital structure change. While it relates to a General Meeting (AGM-R) and a share issue (SHA), the primary function of this specific RNS release is to declare the official results of the shareholder vote on the resolutions, which aligns closely with 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Since it is a formal regulatory announcement distributed via RNS detailing voting outcomes, DVA is the most specific fit, although RNS is also applicable as the distribution channel. Given the explicit mention of 'Result of General Meeting' and the passing of resolutions, DVA is chosen over the general RNS category.
2018-09-21 English
Contract with top 10 global pharmaceutical company
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory news service announcement from the London Stock Exchange. The content details a 'Significant new contract' won by IXICO plc, including the value (£9.1m) and the nature of the work (Phase III clinical trial support). This is a specific business development announcement, not a full financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). Since it is a formal announcement disseminated via the RNS system regarding a significant business event (a major contract win), it fits best under the general Regulatory Filings category (RNS) as it is a material event disclosure, although it could also be considered a Capital/Financing Update if the contract implied immediate funding, but here it is primarily operational news disclosed via RNS. Given the structure and the explicit RNS header, RNS is the most appropriate classification for a general material announcement not covered by more specific codes like ER or MANG.
2018-09-11 English
Proposed Capital Reorganisation
Capital/Financing Update Classification · 1% confidence The document is clearly identified as an RNS announcement (RNS Number : 4944Z) from IXICO plc, dated 03 September 2018. The content details a 'Proposed Capital Reorganisation' and the 'Notice of General Meeting' required to approve it. This announcement describes a significant change to the company's capital structure (consolidation and sub-division of shares) and the associated shareholder vote. This falls under the category of Capital/Financing Update (CAP) as it directly concerns capital structure changes, although it also involves a General Meeting notice. Since the core subject is the capital reorganisation, CAP is the most specific fit. It is not the actual AGM material (AGM-R), nor is it a general share issue (SHA) or a buyback (POS), but a specific structural change requiring shareholder approval. Given the explicit mention of capital reorganisation and shareholder approval for structural changes, CAP is the primary classification.
2018-09-03 English
Contract expansion with biopharmaceutical company
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated August 30, 2018. The content announces a business development event: the expansion of a contract with a biopharmaceutical company, increasing the total contract value. This is a specific, material operational update that is being disseminated via the RNS system (Regulatory News Service). While it is a business update, it is not a standard financial report (like 10-K, IR, ER, or MRQ). It is a specific announcement of a contract change. Since it is distributed via RNS and concerns a specific corporate event that doesn't fit the other specific categories (like DIRS, DIV, CAP, or MANG), the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly labeled as an RNS filing.
2018-08-30 English
Trading Statement
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is an update on trading performance for the financial year ending 30 September 2018, indicating expected revenue figures ahead of market expectations. This is a preliminary announcement of financial results, not the full comprehensive report (10-K or IR). The content focuses on key financial highlights (revenue increase, reduced operating loss expectation) and future outlook, which aligns perfectly with the definition of an Earnings Release (ER). Although it is distributed via RNS, the content itself is an ER, which takes precedence over the general 'RNS' category.
2018-08-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.